AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and obesity in SUMMIT
Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
News Medical3h
Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss
Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Armed robbery in Revesby18h
Anti-Obesity Drugs, Lifestyle Boost Heart Health
Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the ...
Tirzepatide lowered risk of worsening heart failure and CVD death for obese adults
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
On Saturday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced ...